Save billions or stick with Humira? Drug brokers steer Ameri

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

Related Keywords

New York , United States , Brooklyn , Kentucky , Denmark , California , Poland , Tennessee , United Kingdom , Americans , American , Michael Thompson , Cora Opsahl , Richard Gonzalez , Greg Baker , Coherus Biosciences , Antonio Ciaccia , Alex Jung , Siddharth Singh , Madelaine Feldman , Mark Cuban , Rachel Shubert , Juliana Reed , Kaiser Permanente , Mary Beth Lang , Keith Athow , Kevin Ali , Paul Holmes , American College Of Rheumatology , Kroger , Midwest Business Group On Health , Biosimilars Forum , American Gastroenterological Association , Health News , National Alliance Of Healthcare Purchaser Coalitions , Service Employees International Union , Bj Health Fund , Arthur Allen , Williams Barber Morel , Express Scripts , Federal Trade Commission , Blue Shield , Cost Plus Drugs , Sue Lee , National Alliance , Healthcare Purchaser , Midwest Business Group , Marcus Snow , American College , New Orleans , Gastroenterological Association , Inflation Reduction Act , Rich Lieblich ,